Spots Global Cancer Trial Database for Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
Official Title: Phase I Study of Oral Darinaparsin in Advanced Solid Tumors
Study ID: NCT01139346
Conditions
Interventions
Study Description
Brief Summary: This study is a Phase I, dose escalation study of oral darinaparsin for the treatment of advanced solid tumors. Eligible patients could have received any amount of previous therapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Lafayette, Indiana, United States
, Dallas, Texas, United States
, Houston, Texas, United States
Contact Details
Name: Jonathan J. Lewis, MD, PhD
Affiliation: ZIOPHARM, Oncology, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
